COMMUNIQUÉS West-GlobeNewswire

Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event
28/08/2025
KYV-101 has the potential to deliver durable, drug-free, disease-free remission in myasthenia gravis and set a new treatment standard for stiff person syndrome Innovative FDA-aligned KYSA-6 Phase 3 trial design for [...]
Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
28/08/2025
HOUSTON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of [...]
Tidewave Bio Completes FDA INTERACT Meeting for TBC-1, a Universal Cell Therapy Platform in Solid Tumors
28/08/2025
LOS ANGELES, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tidewave Bio, a biotechnology company developing a universal, off-the-shelf, gene-enhanced antigen-presenting cell therapy platform, today announced the successful [...]
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
28/08/2025
CORAL GABLES, Fla., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and [...]
Candel Therapeutics to Participate in Upcoming Investor Conferences in September
28/08/2025
NEEDHAM, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]
IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
28/08/2025
LAWRENCEVILLE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN) , a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the Company has regained [...]
Scottish Medtech Seluna Launches Pediatric Sleep Trial Ahead of U.S. Entry
28/08/2025
Seluna seeks US collaborations and investment to transform childhood sleep disorder diagnosis globally Glasgow, UK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Scottish Medtech Seluna Launches Pediatric Sleep Trial Ahead of U.S. [...]
NurExone Biologic Inc. Announces Second Quarter 2025 Financial Results
28/08/2025
TORONTO and HAIFA, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a preclinical-stage biotechnology company pioneering exosome- [...]
Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss
28/08/2025
Generic Saxenda ® is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the U.S. market. This approval and launch add to Teva’s continued commitment to [...]
Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds
28/08/2025
HOUSTON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat [...]
Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference
28/08/2025
DOYLESTOWN, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific [...]
CytoDyn to Present at the H.C. Wainwright 27th Annual Global Investment Conference
28/08/2025
VANCOUVER, Washington, Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage biotechnology company advancing leronlimab, a first-in-class humanized monoclonal [...]
Streamex (BSGM) to Participate in the 5th Annual Needham Virtual Crypto 1x1 Conference on September 4th
28/08/2025
LOS ANGELES, CA & VANCOUVER, BC , Aug. 28, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (“BioSig” or the “Company”), which recently merged with Streamex Exchange Corporation (“Streamex”) (NASDAQ: BSGM), a gold [...]
Vericel to Present at the Wells Fargo Healthcare Conference on Thursday, September 4, 2025
28/08/2025
CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will [...]
CorMedix to Participate in Upcoming Investor Conferences
28/08/2025
BERKELEY HEIGHTS, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening [...]
PolarityBio to Share Regenerative Wound Healing Expertise at SAWC Fall 2025
28/08/2025
SALT LAKE CITY, Aug. 28, 2025 (GLOBE NEWSWIRE) -- PolarityBio , a clinical-stage biotechnology company focused on addressing unmet needs in wound healing through innovation in autologous regenerative skin multicellular [...]
The International Myeloma Foundation Revives ‘Do You #kNOwMyeloma?’ for Blood Cancer Awareness Month 2025
28/08/2025
STUDIO CITY, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- With Blood Cancer Awareness Month coming up this September, the International Myeloma Foundation (IMF) is reviving and amplifying its highly successful #kNOwMyeloma [...]
Can-Fite Reports H1 2025 Financial Results and Clinical Update
28/08/2025
Ramat Gan, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological [...]
Oculis to Participate in Upcoming September Investor Conferences
28/08/2025
ZUG, Switzerland, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovative solutions for ophthalmic and neuro- [...]

Pages